Effects of neutral endopeptidase (Neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: Studies with thiorphan and omapatrilat

Cardiovascular Therapeutics

Volumn 32, Issue 1, 2014, Pages 13-18

  Dalzell, Jonathan R ^a   Seed, Alison ^a   Berry, Colin ^a   Whelan, Carol J ^a   Petrie, Mark C ^a   Padmanabhan, Neal ^a   Clarke, Amanda ^b   Biggerstaff, Fiona ^b   Hillier, Christopher ^c   Mcmurray, John J V ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF THE WEST INDIES   (Jamaica)

Author keywords

Adrenomedullin; Bradykinin; Neprilysin; Neutral endopeptidase; Omapatrilat; Vasopeptidase inhibitor

Indexed keywords

ADRENOMEDULLIN; ANGIOTENSIN I; BIG ENDOTHELIN 1; BRADYKININ; CALCITONIN GENE RELATED PEPTIDE; CAPTOPRIL; MEMBRANE METALLOENDOPEPTIDASE; NATRIURETIC PEPTIDE TYPE C; OMAPATRILAT; SUBSTANCE P; THIORPHAN; VASOACTIVE INTESTINAL POLYPEPTIDE; VASODILATOR AGENT; VASOPEPTIDASE INHIBITOR;

ADULT; ARTERY; ARTICLE; BLOOD VESSEL; CARDIOVASCULAR FUNCTION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CORONARY ARTERY DISEASE; ENZYME INHIBITION; FEMALE; HUMAN; IN VITRO STUDY; LEFT VENTRICULAR SYSTOLIC FUNCTION; MALE; MIDDLE AGED; PRIORITY JOURNAL; VASOMOTOR REFLEX;

ADRENOMEDULLIN; BRADYKININ; NEPRILYSIN; NEUTRAL ENDOPEPTIDASE; OMAPATRILAT; VASOPEPTIDASE INHIBITOR;

ADRENOMEDULLIN; AGED; ANGIOTENSIN I; ARTERIES; CAPTOPRIL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEPRILYSIN; PROTEASE INHIBITORS; PYRIDINES; SUBSTANCE P; THIAZEPINES; THIORPHAN; VASODILATION;

EID: 84892535795     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12053     Document Type: Article

References (34)

1. Burnett JC Jr. Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertension 1999;17:S37-S43.
2. Corti R, Burnett JC Jr, Rouleau JL, Ruschitzka F, Lüscher TF. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation 2001;104:1856-1862.
3. Rouleau JL, Pfeffer MA, Stewart DJ, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000;356:615-620.
4. Ferdinand K, Saini R, Lewin A, Yellen L, Barbosa JA, Kushnir E. Efficacy and safety of omapatrilat with hydrochlorothiazide for the treatment of hypertension in subjects nonresponsive to hydrochlorothiazide alone. Am J Hypertens 2001;14:788-793.
5. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, Swedberg K. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002;106:920-926.
6. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004;17:103-111.
7. Coats AJ. Omapatrilat - the story of Overture and Octave. Int J Cardiol 2002;86:1-4.
8. Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010;375:1255-1266.
9. Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012;380:1387-1395.
10. McMurray JJ, Packer M, Desai AS, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 2013;15:1062-1073.
11. Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide, and some C-receptor ligands by endopeptidase-24.11. Biochem J 1993;291:83-88.
12. Nagatomo Y, Kitamura K, Kangawa K, Fujimoto Y, Eto T. Proadrenomedullin N-terminal 20 peptide is rapidly cleaved by neutral endopeptidase. Biochem Biophys Res Commun 1996;223:539-543.
13. Skidgel RA, Engelbrecht S, Johnson AR, Erdös EG. Hydrolysis of substance P and neurotensin by converting enzyme and neutral endopeptidase. Peptides 1984;5:769-776.
14. Yamaguchi T, Kohrogi H, Kawano O, Ando M, Araki S. Neutral endopeptidase inhibitor potentiates endothelin-1-induced airway smooth muscle contraction. J Appl Physiol 1992;73:1108-1113.
15. Hillier C, Berry C, Petrie MC, O'Dwyer PJ, Hamilton C, Brown A, McMurray J. Effects of urotensin II in human arteries and veins of varying caliber. Circulation 2001;103:1378-1381.
16. Coats P, Johnston F, MacDonald J, McMurray JJ, Hillier C. Endothelium-derived hyperpolarizing factor: identification and mechanisms of action in human subcutaneous resistance arteries. Circulation 2001;103:1702-1708.
17. Hillier C, Petrie MC, Love MP, Johnston F, MacLean MR, McMurray JJ. Effect of adrenomedullin on the production of endothelin-1 and on its vasoconstrictor action in resistance arteries: evidence for a receptor-specific functional interaction in patients with heart failure. Clin Sci (Lond), 2001;101:45-51.
18. Petrie MC, Padmanabhan N, McDonald JE, Hillier C, Connell JM, McMurray JJ. Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol 2001;37:1056-1061.
19. Erdos EG, Skidgel RA. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J 1989;3:145-151.
20. Bevan EG, Connell JM, Doyle J, et al. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens 1992;10:607-613.
21. Richards AM, Wittert GA, Crozier IG, Espiner EA, Yandle TG, Ikram H, Frampton C. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens 1993;11:407-416.
22. Richards AM, Wittert GA, Espiner EA, Yandle TG, Ikram H, Frampton C. Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. Circ Res 1992;71:1501-1507.
23. Ferro CJ, Spratt JC, Haynes WG, Webb DJ. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation 1998;97:2323-2330.
24. Petrie MC, Hillier C, Johnston F, McMurray JJ. Effect of neutral endopeptidase inhibition on the actions of adrenomedullin and endothelin-1 in resistance arteries from patients with chronic heart failure. Hypertension 2001;38:412-416.
25. Fryer RM, Segreti J, Banfor PN, et al. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol 2008;153:947-955.
26. Kim KS, Kumar S, Simmons WH, Brown NJ. Inhibition of aminopeptidase P potentiates wheal response to bradykinin in angiotensin-converting enzyme inhibitor-treated humans. J Pharmacol Exp Ther 2000;292:295-298.
27. Cataliotti A, Boerrigter G, Chen HH, et al. Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure. Circulation 2002;105:639-644.
28. Rabkin SW, Klassen SS. Omapatrilat enhances adrenomedullin's reduction of cardiomyocyte cell death. Eur J Pharmacol 2007;562:174-182.
29. Nishikimi T, Mori Y, Ishimura K, et al. Chronic effect of combined treatment with omapatrilat and adrenomedullin on the progression of heart failure in rats. Am J Hypertens 2006;19:1039-1048.
30. Ishimura K, Nishikimi T, Akimoto K, Ono H, Kangawa K, Matsuoka H. Renoprotective effect of long-term combined treatment with adrenomedullin and omapatrilat in hypertensive rats. J Hypertens 2005;23:2287-2296.
31. Lisy O, Jougasaki M, Schirger JA, Chen HH, Barclay PT, Burnett JC Jr. Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin. Am J Physiol 1998;275:F410-F414.
32. Rademaker MT, Charles CJ, Cooper GJ, et al. Combined endopeptidase inhibition and adrenomedullin in sheep with experimental heart failure. Hypertension 2002;39:93-98.
33. Wilkinson IB, McEniery CM, Bongaerts KH, MacCallum H, Webb DJ, Cockcroft JR. Adrenomedullin (ADM) in human forearm vascular bed: effect of neutral endopeptidase inhibition and comparison with proadrenomedullin NH2-terminal 20 peptide (PAMP). Br J Clin Pharmacol 2001;52:159-164.
34. Brandt RR, Mattingly MT, Clavell AL, Barclay PL, Burnett JC Jr. Neutral endopeptidase regulates C-type natriuretic peptide metabolism but does not potentiate its bioactivity in vivo. Hypertension 1997;30:184-190.